Re-appointment of M/s. Manish B. Analkat as the Cost Auditor of the Company for F.Y. 2026-27
CORONA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Corona Remedies reported strong FY2026 results with revenue from operations growing 17.3% to Rs. 1,403.18 Crores from Rs. 1,196.42 Crores in FY2025. Net profit after tax jumped 24% to Rs. 184.85 Crores from Rs. 149.05 Crores, with EPS at Rs. 30.22 versus Rs. 24.37. The Board recommended a 100% final dividend of Rs. 10 per equity share (record date: June 19, 2026). Key leadership appointments include M/s. Walker Chandiok & Co LLP as new Statutory Auditor for 5 years and re-appointment of Dr. Kirtikumar Mehta as Non-Executive Chairman for 5 years from April 2027. The company listed on NSE and BSE in December 2025 via an IPO. One-time exceptional charge of Rs. 19.10 Crores was recorded due to new Labour Codes implementation.
The strong 24% jump in net profit and 100% dividend payout signal healthy financial performance, which could be positive for the stock. The change in statutory auditor from Deloitte is routine but worth monitoring.